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Abstract
Background: Retinoblastoma protein-interacting zinc-finger gene 1 (RIZ1) displays strong tumor suppressive
activities, and its expression is often silenced in many types of human tumors. However, the relationship between
RIZ1 expression and glioma prognosis remains unclear.
Methods: The dysregulation of RIZ1 was evaluated using real-time polymerase chain reaction, western blot, and
immunohistochemical analysis of gliomas from 51 patients. Correlation analysis was performed to examine
relationships between RIZ1 immunoreactivity, clinicopathological features, and patient prognosis. Also, human
malignant glioma U87 and U251 cell lines were stably transduced with ectogenic RIZ1 using a lentiviral vector to
investigate the effects of induced expression of RIZ1 on cell proliferation, cell cycle, and apoptosis.
Results: Real-time polymerase chain reaction and western blot analysis showed that RIZ1 was downregulated in
high-grade gliomas compared with low-grade gliomas and normal brain tissue. Immunohistochemistry showed less
RIZ1 labeling in high-grade gliomas than in low-grade gliomas. There was a negative correlation between RIZ1 and
Ki-67 immunoreactivity. Clinicopathological evaluation revealed that RIZ1 expression was negatively correlated with
tumor grade and patient age. Kaplan-Meier survival analysis showed a positive correlation between RIZ1
immunoreactivity level and progression-free and overall survival times. Multivariate analysis showed that high RIZ1
expression was an independent prognostic factor for patients with gliomas. Induced expression of RIZ1 in U87 and
U251 cells reduced cell proliferation and increased apoptosis, and cell cycle analysis revealed that a majority of cells
were arrested at G2-M. Moreover, transfection with a RIZ1 expression vector increased p53 and caspase-3
expression and decreased p-IKBα and p-AKT protein levels, suggesting that RIZ1 may stimulate p53-mediated
apoptosis and inhibit p-IKBα and p-AKT signaling pathways.
Conclusions: Our results suggest that high RIZ1 labeling is indicative of lower grades of gliomas and is associated
with better progression-free and overall survival rates. Therefore, RIZ1 may be a promising therapeutic target for
patients with gliomas.
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Background
Both anaplastic astrocytomas (World Health Organization
(WHO) grade III) and glioblastoma multiformes (GBMs;
WHO grade IV) are classified as high-grade gliomas
(HGGs), whereas Low-grade gliomas (LGGs) constitute
grades I and II tumors of astrocytic and grade II tumors of
oligodendroglial lineage. Compared with LGGs, HGGs
have the highest annual incident rate (0.005 %) and worst
prognosis. Despite advanced therapies for gliomas, in-
cluding surgery, radiation, and chemotherapy, the
overall 5-year survival rate of GBM remains less than
5 % [1]. Thus, the discovery of new therapies for
HGGs is urgently needed.
Previous studies of HGG pathology have focused on
identifying abnormalities in genetic events and signaling
pathways, characterising tumor stem cells and tumor
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immunology, and exploring novel therapeutic ap-
proaches. However, despite promising new therapeutics
(e.g., gene therapy), an ideal therapeutic target for HGG
remains undefined. Therefore, investigations of the mo-
lecular underpinnings of HGG could provide insights
into the malignancy of glioma cells, the mechanisms
underlying glioma development, and the prediction of
glioma prognosis.
The retinoblastoma protein-interacting zinc-finger
gene 1 (RIZ1), which is closely related to cancer genesis,
is located within tumor suppressor gene clusters on
chromosome 1q36. The RIZ1 gene encodes a methyl-
transferase protein containing a PR/SET domain [2–4].
Similar to p53, RIZ1 serves as a cancer suppressor, as its
deletion is observed in various types of human cancers
including breast cancer, liver cancer, colorectal cancer,
neuroblastoma, chronic myelogenous leukemia, and ma-
lignant meningioma [5–9]. However, it remains unclear
whether RIZ1 influences the progression of gliomas.
The aim of the current study was to assess the pattern
of RIZ1 expression in gliomas and its correlation with
clinicopathologic characteristics and patient outcomes.
We found that RIZ1 expression is negatively correlated




Human HGG cell lines U87 and U251 were obtained
from the Chinese Academy of Sciences (Shanghai,
China). Both cell lines were grown in Dulbecco’s Modi-
fied Eagle’s Medium with 8 % fetal bovine serum (FBS),
100 U/ml penicillin G, and 100 μg/ml streptomycin. The
human breast cancer cell line MCF-7 was purchased
from American Tissue Culture Collection (Manassas,
VA) and was cultured in the same medium with 10 %
FBS, 100 U/ml penicillin, and 100 mg/ml streptomycin.
All cells were cultured at 37 °C in humidified air with
5 % CO2.
Patients and tissue samples
The study protocol was examined and approved by the
Shanghai Changzheng Hospital Ethics Committees. Prior
to surgery, all patients were given informed written con-
sent based on the Declaration of Helsinki. There were
32 males and 19 females (male-to-female ratio = 1.68:1.0)
enrolled in the study, and the median age was 46 years
(range, 22–75 years). The follow-up period ranged from
3–64 months. Clinicopathologic characteristics of pa-
tients are summarised in Table 1. The median
progression-free survival (PFS) and overall survival (OS)
times were 7.5 months (1.0–48.6 months) and
18.3 months, respectively.
All 51 glioma samples (LGG (WHO I and II grade)
12cases, HGG (WHO III and IV grade) 39cases) were
surgically obtained in the Department of Neurosur-
gery at Changzheng Hospital, Shanghai, China, from
March 2008 to December 2012. Immediately after re-
section, samples were divided into two parts: one part
was fixed in formalin, and the other part was snap-
frozen at -80 °C. The formalin-fixed gliomas were
histopathologically graded according to the 2007
WHO classification of tumors of the central nervous
system.
Normal brain tissue (NBT) samples were obtained
from two individuals who died due to traffic accidents
and presented no prior pathological conditions. All spec-
imens were re-examined and stored by the Changzheng
Hospital Institutional Review Board. Tumor size, extent
of surgical resection, and time free from recurrence were
recorded.
Protein extraction and western blotting
The western blot analysis was performed as described
previously [10]. Briefly, proteins were extracted and
transferred onto nitrocellulose membrane (Millipore,
USA). Then, these protein-embedded membranes were
blocked in 5 % non-fat milk in 0.1 M phosphate-
buffered saline (PBS) for 1 h at room temperature. After
wash out in PBS, these membranes were blotted with
primary antibodies overnight and followed by incubation
with a peroxidase-conjugated secondary antibody for 1 h
in room temperature. Enhanced chemiluminescence
(Bio-Rad, Hercules, CA, USA) were used to visualize
blots. The primary antibodies used in this study included
the rabbit polyclonal antibody to RIZ1 (Abcam, Cam-
bridge, USA; at 1:1000 dilution), mouse monoclonal
antibody to P53 (Santa Cruz, 1:1000), goat polyclonal
antibody to caspase-3 (Santa Cruz, 1:1000) and β-actin
(Santa Cruz Biotechnology, Santa Cruz, CA, USA; at
1:1000 dilution). pAkt (S473; cat # 05-736) antibody was
procured from Upstate Cell Signaling (Lake Placid, NY).
Antibodies against p-PI3K (Tyr458; cat 4228 s) were
from Cell Signaling Technologies (Danvers, MA). The
relative amount of protein was quantified by densitom-
etry using Image J software.
Real-time PCR analysis
RNA was extracted from frozen tissue specimens and
glioma cell lines using the RNeasy mini kit (Qiagen, Val-
encia, CA, USA). Reverse transcription was conducted
instantly after RNA extraction in the PrimeScript™ RT
Master Mix (TAKARA, RR036A, Dalian, China). The
qPCR was performed by using the SYBR® Premix Ex
Taq™ (TAKARA, DRR041A, Dalian, China) in the 7500
fast qPCR machine (Applied Biosystems, Foster City,
CA, USA). The qPCR protocol included four steps:
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5 min at 95 °C, 40 cycles of 95 °C for 30 s, 55 °C for 30 s
and 72 °C for 30 s. The forward and reverse primers for
the RIZ1 amplification were 5′- AACATGTGCTGCG
AGGACTT -3′ and 5′- TTCTTCCCTTTCCGGCTCTT
-3′, respectively. The forward and reversed primer se-
quences for the β-actin were 5′- CCAAGGCCAAC
CGCGAGAAGAT -3′ and 5′- TTGCTCGAAGTC
CAGGGCGA -3′, respectively.
Immunohistochemistry staining
Formalin-fixed, paraffin-embedded samples were first
sectioned into 3-mm slides. Then slides were deparaf-
fined in xylol and dehydrated in concentration-graded
ethanol series. After the inactivation of endogenous
peroxidase activity, the sections were heated in micro-
wave for 20 min in 1 mM EDTA buffer (pH 8.0) to
retrieve antigen. The sections were then blocked with
1 % bovine serum albumin for 40 min. Then, primary
RIZ1 antibody (ab3790, Abcam) at 1:50 or Ki-67 pri-
mary antibody (ab15580, Abcam) at 1:75 overnight
were incubated with slides at 48C overnight. Next
day, primary antibodies were washed out and slides
were incubated with biotin-conjugated secondary anti-
body for 20 min at room temperature. The
peroxidase-conjugated biotin–streptavidin complex
(Dako) was used for visualization.
Evaluation of immunostaining
All sections were examined microscopically and scored
by two independent pathologists who were blinded to
the clinical diagnosis. Both Ki-67 and RIZ1 labeling
index were recorded. The labeling index was defined as
mean percentage by counting the positive staining of
tumor cells for 1000 cells in three most-labeled areas.
For calculating labeling index, tissue slides were divided
into five levels: (1) immunoreactivity completely absent
(negative, 0 %); (2) <5 %; (3) <25 %; (4) <50 %; and (5)
up to 100 %.
Cell culture and transfection studies
The human glioblastoma cell lines U87 and U251
were cultured as previously described. RIZ1 expres-
sion vector pCMV-RIZ1 and its control pCMV-GFP
were prepared as previously described [9]. The estab-
lishment of stable transfectant glioblastoma cell lines
U87 and U251 with the pCMV-RIZ1 or pCMV-GFP
respectively were conducted as described by the
manufacturer (Lipofectamine 2000, Invitrogen). After
48 h of incubation, the stable transfectant was
screened and established by flow cytometry. And the
expression product was tested for RIZ1 expression by
Western blot.
Table 1 Correlation between RIZ1 immunoreactivity and clinicopathologic features
RIZ1 immunoreactivity (Median = 8.0)
Features N(N = 51, %) <Median ≥Median P-values
Gender 0.097
Male 32(62.7) 19 13
Female 19(37.3) 6 13
Age 0.027*
< 50 years 29(56.9) 12 17
≥ 50 years 22(43.1) 13 9
Tumor diameter 0.324
< 6 cm 32(62.7) 14 18
≥ 6 cm 19(37.3) 11 8
Extent of resection 0.436
Gross-total 39(76.5) 20 19
Sub-total 12(23.5) 5 7
Pathological grade 0.000*
Low grade 12(23.5) 1 11




* P < 0.05 was considered statistically significant
Table 1: Clinicopathological evaluation suggested that RIZ1 expression was associated with tumor grade (p = 0.000) and patient age (P = 0.027)
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Cell cycle assay
PCMV-RIZ1 or pCMV-GFP cells were harvested, centri-
fuged at 1000 r.p.m. for 5 min, resuspended in phos-
phate buffered saline and incubated with 0.2 mg/ml
propidium iodide (PI) containing 1 mg/ml RNase A
(Sigma) for 10 min in the dark. Distribution of the cell
cycle was quantitated by flow cytometry analysis. Data
were collected from three different experiments and an-
alyzed by BD Cell quest computer program.
Apoptosis assay
Cell pellets collected and centrifuged at 1000 rpm for
5 min were washed with PBS and resuspended in 200 μl
1X binding buffer, mixed with 5 μL of annexin V-FITC
and 10 μL of PI according to manufacturer’s instruc-
tions, and then incubated at room temperature for
5 min in the dark. Subsequently, cells stained by
Annexin V-fluorescein isothiocyanate (FITC)/ propidium
iodide (PI) were analyzed using luorescence-activated
cell sorter (FACS) analysis.
BrdU
BrdU (5-bromo-2′-deoxyuridine) Cell Proliferation
Assay (chemiluminescence) was performed as manufac-
ture’s procedure (Roche, Germany). Briefly, cells (1 ×
105) under different treatments were plated onto 96-well
plates. Then, incubate the various types of cell line with
Brdu labeling solution for 24 h. After removal of the la-
beling solution and fixing the cells, incubate cells with
anti-BrdU Detection Antibody. Washing and adding
substrate solution to each well, measure the light emis-
sion of samples in a microplant luminometer. Three in-
dependent experiments were performed.
Statistics
All statistical analysis was performed in the SPSS 21.0
(IBM, Endicott, NY USA). The graphs were generated
by Graphpad Prism 5 (GraphPad Software, Inc., La Jolla,
CA, USA). The Kruskal–Wallis test was used to com-
pare the immunolabeling results between the glioma tis-
sue grades. The correlation between RIZ1 and Ki-67
intensity was examined by Spearman’s correlation coeffi-
cient. Univariate survival analysis was performed using
the Kaplan–Meier method and analyzed by the log-rank
test to assess survival differences between groups. Six
possible prognostic factors were analyzed by univariate
analysis for potential association with survival. Factors
with a result of P < 0.2 in the univariate analysis were in-
cluded in multivariate analysis for potential association
with survival. P value of <0.05 was considered statisti-
cally significant.
Fig. 1 RT-PCR analysis of RIZ1 mRNA expression in different grade of gliomas as well as in U87 and U251 GBM cell lines (a). II: LGG, III and IV:
HGG. Human breast cancer MCF-7 cells served as a positive control. PFS (b) and OS (c) associated with RIZ1 immunoreactivity in patients with
gliomas. Three independent experiments were performed. *P < 0.05 as compared with control groups
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Fig. 3 Immunohistochemical expression of RIZ1 (a: A–C) and Ki-67 (a: D–F) in NBT and gliomas. Quantitative analysis of RIZ1 (b) and Ki-67 (c)
immunohistochemical expression in gliomas. The correlation between amount of RIZ1 and Ki-67 labeling (d)
Fig. 2 Western blot analysis of RIZ1 protein expression levels in NBT, LGGs (II), and HGGs (III and IV) as well as GBM cell lines (a, c). b, d
Quantification of (a, b). Three independent experiments were performed. *P < 0.05 vs. NBT and LGG
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Results
Downregulation of RIZ1 in HGG and GBM cell lines
Real-time polymerase chain reaction (RT-PCR) showed
greatly reduced RIZ1 expression in HGGs, whereas
R1Z1 was readily detectable in NBT and low-grade gli-
omas (LGGs) (Fig. 1a). Western blotting analysis demon-
strated undetectable levels of R1Z1 expression in HGGs
and a downregulation of RIZ1 protein expression in
LGGs compared with NBT (Fig. 2a, b). Therefore, the
level of RIZ1 expression was negatively correlated with
the grade of gliomas. These results were replicated in
human GBM (WHO IV) cell lines U87 and U251 (Fig. 1a
and Fig. 2c,d).
RIZ1 immunohistochemical expression in gliomas
Immunohistochemistry showed strong RIZ1 staining in
the cytoplasm of NBT and LGGs, whereas a progressive
loss of cytoplasmic RIZ1 staining was detected in HGGs
(Fig. 3a). Statistical analysis confirmed reduced RIZ1 la-
beling in HGGs compared with LGGs (7.55 ± 4.39 % vs.
48.83 ± 4.34 %, p < 0.0001; Fig. 3b). Labeling of Ki-67, a
proliferation marker detected in cell nuclei, was sig-
nificantly higher in HGGs than in LGGs (40.10 ±
10.17 % vs. 6.92 ± 1.96 %, p < 0.0001; Fig. 3c). RIZ1
and Ki-67 immunoreactivity were negatively correlated
(Spearman’s r = -0.8274, p < 0.0001; Fig. 3d).
Correlation between RIZ1 immunoreactivity and
clinicopathological features
To determine whether RIZ1 expression is associated
with clinicopathological parameters, we performed cor-
relations between RIZ1 expression and patient age,
tumor histological grading, and other clinical features
(Table 1). We found strong negative correlations be-
tween RIZ1 labeling and tumor grade (p < 0.0001) and
patient age (p = 0.027).
Relationship between RIZ1 immunoreactivity and patient
prognosis
Kaplan-Meier survival analysis revealed a significant
positive correlation between RIZ1 immunoreactivity and
PFS (p < 0.0001; Fig. 1b). The probability of OS was also
higher for glioma patients who exhibited higher RIZ1
expression (p < 0.0001) (Fig. 1c). Univariate survival
analysis revealed significant relationships between RIZ1
expression, Ki-67 expression, and patient prognosis,
whereas no significant associations were found between
prognosis and patient age, gender, tumor size, or extent
of resection (Table 2). Multivariate analysis using a Cox
proportional hazards model with all the variables in-
cluded in the univariate analysis revealed that high RIZ1
expression was an independent prognostic factor for pa-
tients with glioma (Table 3). Together, these results sug-
gest that RIZ1 expression is a key predictor of survival
in patients with gliomas.
Induced expression of RIZ1 in glioma cells inhibits cell
proliferation and induces G2-M arrest
Next, we investigated the ability of RIZ1 to suppress
growth of the glioblastoma cell lines U87 and U251.
Transfection of pCMV-RIZ1 into U87 and U251 cells re-
duced both BrdU incorporation. However, no reduction
of BrdU incorporation were observed after transfection
with pCMV-green fluorescent protein (GFP) (Fig. 4).
Further cell cycle analysis revealed that a majority of
cells were arrested at G2-M 72 h after pCMV-RIZ1 in-
fection (Figs. 5 and 6). By contrast, pCMV-GFP-infected
cells showed no differences from parental U87 and U251
cells. Therefore, these results suggest that RIZ1 inhibits
cell proliferation by inducing cell cycle arrest at the G2-
M phase.
Overexpression of RIZ1 in U87 and U251 cells induces
apoptosis
Finally, we began to explore the effect of RIZ1 overex-
pression on apoptosis in U87 and U251 cell lines. The
number of apoptotic U87 and U251 cells were signifi-
cantly increased by transfection with pCMV-RIZ1 (Figs. 7
and 8). To further investigate the molecular mechanism
by which RIZ1 inhibits glioma cell growth or induces
Table 3 Multivariate analysis using the Cox proportional
hazards revealed that expression level of RIZ1 is an independent
prognostic factors for patients with gliomas
variable B SE Wald df Sig. Exp(B) 95.0 % CI for Exp(B)
Lower Upper
RIZ1 -1.808 0.426 17.997 1 0.000 0.164 0.071 0.378
Table 2 Kaplan-Meier univariate survival analysis of the relationship between clinicopathologic features and patient prognosis
Variables Median Survival (months, 95 % CI) P-values (log-rank) Multi-p
RIZ1 (<Median vs. ≥Median) 12.000(9.324-14.676) 36.000(32.378-39.622) <0.0001 0.000
Ki-67 (<Median vs. ≥Median) 36.000(32.814-39.186) 12.500(7.314-17.686) 0.001 0.202
Age (<50 vs. ≥50 years) 29.100(1.272-56.928) 16.000(6.600-25.400) 0.133 0.679
Gender (Male vs. Female) 14.000(9.149-18.851) 33.800(22.536-45.064) 0.469 NA
Diameter (≥6 cm vs. < 6 cm) 13.300(0.000-29.135) 28.000(7.468-48.532) 0.710 NA
Extent of resection (Gross vs. Sub) 23.8(7.158-40.442) 12.000(8.318-15.682) 0.706 NA
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Fig. 5 Effect of pCMV-RIZ1 on cell cycle in U87 cells. The data are the mean ± SD of one representative experiment. Similar results were obtained
in three independent experiments. b statistical analysis of (a). *P < 0.05 vs control group
Fig. 4 Induced expression of RIZ1 in U87 (a) and U251 (b) cells inhibited cell proliferation as measured by BrdU incorporation. The rlu/s in the Y
axis represents the relative light units/second. Three independent experiments were performed. *P < 0.05 as compared with control groups
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apoptosis, we investigated whether RIZ1 affects the ex-
pression of p53. When transfected with pCMV-RIZ1,
U87 and U251 cells exhibited elevated p53 and caspase-
3 expression levels (Fig. 9). Furthermore, protein levels
of p-IKBα and p-AKT were significantly lower in trans-
fectants with higher RIZ1 expression as compared with
control groups, whereas expression level of total IKBα
and AKT were unchanged (Figs. 10 and 11). Therefore,
RIZ1 may stimulate p53-mediated apoptosis in U87 cells
and inhibit p-IKBα and p-AKT signaling pathways in gli-
oma pathogenesis, although the specific pathways in-
volved need further investigation.
Discussion
RIZ1 is tightly linked to the progression of various types
of cancers, as mutation, deletion, and altered DNA
methylation of RIZ1 has been found in several human
cancers [11–13]. Similar to p53, RIZ1 is a potential
tumor suppressor that could serve as a novel target of
cancer therapy. Previous study using PCR/SSCP found
RIZ1 was not the target-gene mapped at 1p involved by
mutation in oligodendroglioma development [14]. How-
ever, the expression level of RIZ1 in HGGs and its role
in glioma pathogenesis remain unclear.
The present study demonstrates that RIZ1 expression
was significantly inhibited in glioma samples (both HGGs
and LGGs) compared with NBT. Considering glioma tis-
sue, HGGs showed a greater reduction in RIZ1 levels than
LGGs. This pattern of RIZ1 expression suggests the po-
tential function of RIZ1 as a tumor suppression gene. Fur-
thermore, HGGs showed a greater loss of cytoplasmic
RIZ1 staining than LGGs, which agrees with previous
studies using other human tumor samples [7–9]. We also
found that RIZ1 expression was negatively associated with
expression of Ki-67, which is known to be involved in cell
proliferation. Thus, our results suggest that RIZ1 is a
Fig. 6 Effect of pCMV-RIZ1 on cell cycle in U251 cells. The data are the mean ± SD of one representative experiment. Similar results were obtained
in three independent experiments. b statistical analysis of (a). *P < 0.05 vs control group
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Fig. 8 Effect of pCMV-RIZ1 on cell apoptosis in U251 cells. The data are the mean ± SD of one representative experiment. Similar results were
obtained in three independent experiments. b statistical analysis of (a). *P < 0.05 vs control group
Fig. 7 Effect of pCMV-RIZ1 on cell apoptosis in U87 cells. The data are the mean ± SD of one representative experiment. Similar results were
obtained in three independent experiments. b statistical analysis of (a). *P < 0.05 vs control group
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Fig. 10 Western blotting analysis of pCMV-RIZ1 transfection for 72 h on p-IKBα, IKBα, p-AKT and AKT expression in U87 cells. b Quantification of
(a). *P < 0.05 vs control group
Fig. 9 Western blotting analysis of pCMV-RIZ1 transfection for 72 h on p53, and caspase-3 expression in U87 (a) and U251 (c) cells. b, d
Quantification of (a, c). *P < 0.05 vs control group
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potent suppressor of gliomas. Additionally, Kaplan-Meier
survival and multivariate analyses indicated a role for
RIZ1 as a prognostic factor for glioma. Collectively, there-
fore, RIZ1 may be an important factor in the inhibition of
glioma progression, and its expression could be used as a
predictor of patient prognosis.
The mechanism of RIZ1 in cancer suppression had
been widely studied. The most popular hypothesis is that
RIZ1 causes G2-M arrest and apoptosis via cooperation
with p53 [7–9]. Nest, we chosen U87 and U251 cell lines
for the functional studies. Because U87 and U251 could
represent the behavior of HGGs and they were the most
available and deeply studied cell lines in our lab. And we
have done lots of serial explorations in them with differ-
ent genes and got excellent results [15–17]. Consistent
with above hypothesis, we found that induced expression
of RIZ1 in U87 and U251 cells inhibited cell prolifera-
tion, increased the number of apoptotic cells, and
arrested cells at the G2-M phase. Furthermore, previous
studies show that simultaneous RIZ1 and p53 deficien-
cies promote tumor formation in both mice and humans
[18, 19], and DNA methylation of RIZ1 gene may be as-
sociated with nuclear accumulation of p53 [20]. Add-
itionally, many sporadic human cancers are associated
with both p53 mutations and RIZ1 silencing [7, 18]. One
recent paper reported a tight relationship between RIZ1
and p53 due to a positive feedback circuit [21]. RIZ1 as
a tumor regulatory protein is very likely to be involved
in the regulation of inflammatory responses. Noman AS
et al [21] reported that LPS significantly augmented the
expression of RIZ1 and the augmentation was mediated
by the activation of nuclear factor (NF)-κB and Akt.
However, in our study, we found that RIZ1 stimulated
p53-mediated apoptosis in U87 and U251 cells and
inhibited p-IKBα and p-AKT signaling pathways. The
possible reason is that the role of RIZ1 in inflammation
response and cancer progression is quite different, and
even the opposite. Future studies are required to clarify
the interaction between RIZ1 and p53, and other signal-
ing pathways in glioma pathogenesis.
Conclusions
Our study provides direct evidence that RIZ1 is tightly
associated with glioma malignancy. We believed that
RIZ1 inhibits glioma progression and thus could be a
potential therapeutic target for patients with gliomas.
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